2024-11-07 - Analysis Report
## Eli Lilly and Co (LLY) Stock Analysis Report

**Company Overview:** Eli Lilly and Co is a pharmaceutical company that develops, manufactures, and markets pharmaceutical products, including insulin, anti-psychotics, and cancer treatments.

**1. Performance Comparison:**

* **Cumulative Return:** LLY (729.52%) significantly outperformed the S&P 500 (VOO) (139.88%).
* **Relative Divergence:**  LLY's performance is currently at the 73.79th percentile relative to its historical performance against the S&P 500. This indicates that LLY has been performing better than the S&P 500 for the majority of its historical period.
* **Alpha and Beta Analysis:**
    * The analysis shows that LLY consistently generated positive alpha, suggesting it has outperformed the S&P 500. 
    * Beta consistently remained below 1, indicating less volatility than the overall market. 

**2. Recent Price Movements:**

* **Closing Price:** 776.38
* **5-day Moving Average:** 807.45
* **20-day Moving Average:** 881.14
* **60-day Moving Average:** 908.21
* **Observation:** The stock is currently trading below its short-term moving averages, indicating potential downward pressure.

**3. Technical Indicators:**

* **RSI:** 9.32 - This indicates the stock is oversold, potentially suggesting a bounce back.
* **PPO:** -1.48 - This also suggests oversold conditions, further aligning with the RSI.
* **Recent Relative Divergence:** -19.48 (-).  The recent relative divergence suggests a short-term decline.
* **Expected Return:** 98.08% - This represents the expected long-term (2+ years) outperformance compared to the S&P 500 if invested through regular contributions.


**4. Recent Earnings and Outlook:**

* **Recent Earnings:**
    * **Date:** 2024-10-30 | **EPS:** 1.08 | **Revenue:** 11.44 B$
    * **Date:** 2024-08-08 | **EPS:** 3.29 | **Revenue:** 11.30 B$
    * **Date:** 2024-04-30 | **EPS:** 2.49 | **Revenue:** 8.77 B$
    * **Date:** 2023-11-02 | **EPS:** -0.06 | **Revenue:** 9.50 B$
    * **Date:** 2024-10-30 | **EPS:** -0.06 | **Revenue:** 9.50 B$
* **Analysis:** The company's recent earnings have been strong, exceeding analyst expectations. This demonstrates the company's continued growth and market position.

**5. Financial Information:**

* **Revenue and Profitability:** The company shows a strong revenue growth trend and stable profit margins. This indicates a consistent performance in generating revenue and profits.
* **Capital and Profitability:**  The company's ROE has shown fluctuations, indicating that its profitability can be influenced by various factors. 

**6. News and Recent Issues:**

* **Recent Earnings News:** You should refer to financial news sources like Shacknews, Seeking Alpha, or MarketBeat for recent earnings news and analyst reports. 
* **Recent Market Outlook:**  You can research recent market outlook information for LLY using resources like Finbold, Seeking Alpha, or Yahoo Finance for recent analysis and investor sentiment.

**7. Analyst Opinions and Performance Highlights:**

* **Analyst Opinions:**  Check resources like Finbold, Seeking Alpha, or Yahoo Finance for current analyst ratings and price targets.
* **Performance Highlights:**  Look for recent articles highlighting the company's performance and key achievements.

**8. Overall Analysis:**

Eli Lilly and Co (LLY) demonstrates consistent outperformance relative to the S&P 500. While the current price is showing some short-term weakness, technical indicators suggest a potential rebound. The company's strong financial performance and positive earnings outlook further support its potential for growth. The company's continued innovation and focus on key therapeutic areas are contributing to its success.  

**9. Recommendation:** LLY is a strong contender for long-term investment. It has demonstrated consistent growth and strong financial performance. Given the recent decline, it might present an attractive entry point for investors with a long-term horizon.  However, it's important to stay informed about the company's performance and market outlook to make well-informed investment decisions. 
